These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Insulin: either alone or combined with oral hypoglycemic agents. Firth RG Prim Care; 1988 Sep; 15(3):665-83. PubMed ID: 3054969 [TBL] [Abstract][Full Text] [Related]
6. Oral hypoglycemic agents in type II diabetes mellitus. Lubbos H; Miller JL; Rose LI Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707 [TBL] [Abstract][Full Text] [Related]
7. Hypoglycemia in hospitalized patients treated with sulfonylureas. Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146 [TBL] [Abstract][Full Text] [Related]
8. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus. Sobieraj DM; Freyer CW Ann Pharmacother; 2010; 44(7-8):1334-7. PubMed ID: 20516361 [TBL] [Abstract][Full Text] [Related]
9. [Knack of treatment with oral hypoglycemic drugs in the elderly]. Komatsu M; Hashizume K Nihon Rinsho; 2006 Jan; 64(1):93-8. PubMed ID: 16408454 [TBL] [Abstract][Full Text] [Related]
10. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Holstein A; Hahn M; Stumvoll M; Kovacs P Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Rosenkranz B Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979 [TBL] [Abstract][Full Text] [Related]
12. Dosing of insulin glargine in the treatment of type 2 diabetes. Barnett A Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716 [TBL] [Abstract][Full Text] [Related]
13. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure. Vallurupalli S Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140 [TBL] [Abstract][Full Text] [Related]
14. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons". Heine RJ Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991 [TBL] [Abstract][Full Text] [Related]
15. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Holstein A; Hammer C; Hahn M; Kulamadayil NS; Kovacs P Expert Opin Drug Saf; 2010 Sep; 9(5):675-81. PubMed ID: 20553106 [TBL] [Abstract][Full Text] [Related]
16. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS. Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670 [TBL] [Abstract][Full Text] [Related]
17. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447 [TBL] [Abstract][Full Text] [Related]
18. [Use of sulfonylurea (SU) in the treatment of diabetes mellitus]. Tasaka Y Nihon Rinsho; 1999 Mar; 57(3):663-8. PubMed ID: 10199151 [TBL] [Abstract][Full Text] [Related]
19. Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype). Pettersson B; Rosenqvist U; Deleskog A; Journath G; Wändell P Diabetes Res Clin Pract; 2011 Apr; 92(1):19-25. PubMed ID: 21195501 [TBL] [Abstract][Full Text] [Related]
20. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]